Not disclosed Neuroscience and Pain 1 is under clinical development by Evotec and currently in Phase I for Pain. According to GlobalData, Phase I drugs for Pain have a 75% phase transition success rate (PTSR) indication benchmark for progressing into Phase II. GlobalData’s report assesses how Not disclosed Neuroscience and Pain 1’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
Not disclosed Neuroscience and Pain 1 overview
The therapeutic candidate is under development for the treatment of unspecified neurological disorder and pain.
Evotec is a drug discovery alliance and development partnership company. It discovers and develops small molecule drugs spanning various conditions areas such as oncology, neurological and nephrological conditions, cardiovascular, inflammation, pain, metabolic and respiratory diseases. Evotec provides drug discovery services such as target identification and validation, sample management, hit identification, in vitro pharmacology services, integrated CMC, and proteomics services. The company has long-term discovery alliances with several leading pharmaceutical companies and development partnerships for product candidates in clinical and pre-clinical development stages. The company has operating facilities in Abingdon and Alderley Park, the UK; Gottingen and Munich, Germany; Orth an der Donau, Austria; Branford, Princeton and Watertown, the US; Verona, Italy; and Toulouse and Lyon, France. Evotec is headquartered in Hamburg, Germany.
For a complete picture of Not disclosed Neuroscience and Pain 1’s drug-specific PTSR and LoA scores, buy the report here.